According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC).
The media release from Active Biotech says that this study is a Phase I trial that will enroll just 30 patients with mCRPC. All eligible patients must be refractory to standard forms of chemotherapy. Additional information about this trial is available on the ClinicalTrials.gov web site. The trial is being conducted exclusively at the Duke Cancer Institute in Durham, North Carolina.
The primary objective for this trial is to identify an appropriate dose of tasquinimod that can be used in combination with cabazitaxel in patients with this highly advanced form of prostate cancer. However, efficacy of the drug combination will also be assessed based on measurements of progression-free and overall survival.
The randomized, double-blind, placebo-controlled, Phase III study of tasquinimod in men with mCRPC (which we have previously discussed at some length) continues to enroll patients.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, Jevtana, mCRPC, metastatic, taquinimod |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply